Illegally Sold Diabetes Treatments Are A Far-Reaching Problem

There are 26 million people in the U.S. who have diabetes, including about 7 million who are undiagnosed, according to the Centers for Disease Control and Prevention. Millions more have pre-diabetes, meaning they have higher than normal blood sugar levels and can reduce their risks of developing diabetes through healthy lifestyle changes, including diet and exercise. “Products that promise an easy fix might be alluring,

Read more

When Given Control Over Monitoring And Medication, High-Risk Patients Are Able To Lower Their Blood Pressure

A new study finds that patients with hypertension who are given control over monitoring their blood pressure as well as making adjustments to their medications are better able to lower their systolic blood pressure than those who use convention treatment. Aimed at those with diabetes, chronic kidney disease or other major cardiovascular risk factors, the study from researchers in the United Kingdom found that putting

Read more

Diabetes Patients On Metformin Show Better Lipid Profile

Chinese researchers found that type 2 diabetes patients taking metformin – one of the first lines of defense in the treatment of the disease – attained a better overall lipid profile compared with those who took glipizide. That’s important news for those with type 2 taking metformin, since 60 percent of all type 2 deaths are related to cardiovascular disease, and higher levels of lipids,

Read more

Eylea Earns FDA Approval To Treat Diabetic Macular Edema

The U.S. Food and Drug Administration has approved the eye drug Eylea for the treatment of diabetic macular edema, according to the drug makers Regeneron Pharmaceuticals, Inc. Diabetic macular edema (DME) is a common complication for those with diabetes. Of the 29.1 million Americans with diabetes, 1.5 million have been diagnosed with DME. This occurs when the blood vessels of the retina are damaged due

Read more

Weekly Dulaglutide Performs Well in Comparison to Daily Liraglutide

A comparison of the effects on A1c between users of once-weekly dulaglutide (made by Eli Lilly and Company) and once-daily liraglutide (sold as Victoza from Novo Nordisk) shows that both drugs have very similar effects. Researchers at Ohio State University conducted a nine-country study of 599 type 2 patients, aged 18 years and older, with A1c’s between 7% and 10%, and taking at least 1,500

Read more

Novo Nordisk Introduces New Insulin Device to U.S. Market

Novo Nordisk has introduced the Levemir® FlexTouch® prefilled insulin delivery device to the U.S. market. The device, filled with insulin detemir [rDNA origin], the first of its kind that does not use a pushbutton extension. In a conventional insulin delivery device, a pushbutton extends out from the device. If the called-for dose is large, an extension may cause problems for the user. In the FlexTouch,

Read more

What Type 2s Can Do When Blood Sugar Soars

The emergency condition most type 2s dread is hypoglycemia, where plummeting blood sugar levels can bring on a dangerous semi-conscious state, and even coma or death. However, hyperglycemia, high-blood sugar levels consistently above 240 mg/dL, can be just as dangerous. Left untreated, at its most extreme high-blood sugar, can induce ketoacidosis, the build-up of toxic-acid ketones in the blood and urine. It can also bring

Read more

Life With Type 2: Lab Rat

Since my diagnosis as a type 2 in 2003, I’ve participated in three Phase 3 drug studies. I am fortunate to live two miles away from one of the San Francisco Bay Area’s premier endocrinologists, Dr. Richard Bernstein (who has the same name as the famous low-carb advocate based on Long Island, New York). Over the years, Dr. Bernstein has established his office as a

Read more